Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. DPD and hENT1 immunohistochemistry and scoring was completed on tumour co...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 March 2018
|
| In: |
British journal of cancer
Year: 2018, Volume: 118, Issue: 7, Pages: 947-954 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-018-0004-2 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1038/s41416-018-0004-2 Verlag, Volltext: https://www.nature.com/articles/s41416-018-0004-2 
|
| Author Notes: | N.O. Elander, K. Aughton, P. Ghaneh, J.P. Neoptolemos, D.H. Palmer, T.F. Cox, F. Campbell, E. Costello, C.M. Halloran, J.R. Mackey, A.G. Scarfe, J.W. Valle, A.C. McDonald, R. Carter, N.C. Tebbutt, D. Goldstein, J. Shannon, C. Dervenis, B. Glimelius, M. Deakin, R.M. Charnley, Alan Anthoney, M.M. Lerch, J. Mayerle, A. Oláh, M.W. Büchler, W. Greenhalf |
| Summary: | Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-fluorouracil/folinic acid (5FU/FA). DPD tumour expression was associated with reduced overall survival (hazard ratio, HR = 1.73 [95% confidence interval, CI = 1.21-2.49], p = 0.003). This was significant in the 5FU/FA arm (HR = 2.07 [95% CI = 1.22-3.53], p = 0.007), but not in the gemcitabine arm (HR = 1.47 [0.91-3.37], p = 0.119). High hENT1 tumour expression was associated with increased survival in gemcitabine treated (HR = 0.56 [0.38-0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80-1.78], p = 0.390). In patients with low hENT1 tumour expression, high DPD tumour expression was associated with a worse median [95% CI] survival in the 5FU/FA arm (9.7 [5.3-30.4] vs 29.2 [19.5-41.9] months, p = 0.002) but not in the gemcitabine arm (14.0 [9.1-15.7] vs. 18.0 [7.6-15.3] months, p = 1.000). The interaction of treatment arm and DPD expression was not significant (p = 0.303), but the interaction of treatment arm and hENT1 expression was (p = 0.009). DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine. |
|---|---|
| Item Description: | Gesehen am 16.08.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-018-0004-2 |